Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT05714345
Trial Phases:	Phase II	Protocol IDs:	ALLO-647-201 (primary) NCI-2023-02445
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Allogene Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT05714345

Summary

The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647
combined with fludarabine and cyclophosphamide compared to fludarabine and
cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in
adults with relapsed or refractory large B-cell lymphoma

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.